Yoshindo Pharmaceuticals, Toyama, announces foundation of joint venture for biosimilars with India’s Lupin Ltd

The new company, YL Biologics, Tokyo, will develop biosimilars such as Embrel (Etanercept), an anti-TNF used as antirheumatic agent.

Yoshindo Pharmaceuticals news release, April 24, 2014

Yoshindo Pharmaceuticals, Toyama, announces foundation of joint venture for biosimilars with India’s Lupin Ltd
Scroll to top